238 related articles for article (PubMed ID: 12570703)
21. The role of cytokines in the establishment, persistence and eradication of the HIV reservoir.
Vandergeeten C; Fromentin R; Chomont N
Cytokine Growth Factor Rev; 2012; 23(4-5):143-9. PubMed ID: 22743037
[TBL] [Abstract][Full Text] [Related]
22. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.
Chun TW; Stuyver L; Mizell SB; Ehler LA; Mican JA; Baseler M; Lloyd AL; Nowak MA; Fauci AS
Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13193-7. PubMed ID: 9371822
[TBL] [Abstract][Full Text] [Related]
23. HIV reservoir dynamics in the face of highly active antiretroviral therapy.
Costiniuk CT; Jenabian MA
AIDS Patient Care STDS; 2015 Feb; 29(2):55-68. PubMed ID: 25412339
[TBL] [Abstract][Full Text] [Related]
24. Modeling HIV persistence, the latent reservoir, and viral blips.
Rong L; Perelson AS
J Theor Biol; 2009 Sep; 260(2):308-31. PubMed ID: 19539630
[TBL] [Abstract][Full Text] [Related]
25. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.
Shen L; Siliciano RF
J Allergy Clin Immunol; 2008 Jul; 122(1):22-8. PubMed ID: 18602567
[TBL] [Abstract][Full Text] [Related]
26. Finding a cure for HIV: will it ever be achievable?
Lewin SR; Evans VA; Elliott JH; Spire B; Chomont N
J Int AIDS Soc; 2011 Jan; 14():4. PubMed ID: 21255462
[TBL] [Abstract][Full Text] [Related]
27. Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individuals.
Fondere JM; Petitjean G; Huguet MF; Salhi SL; Baillat V; Macura-Biegun A; Becquart P; Reynes J; Vendrell JP
J Virol; 2004 Oct; 78(19):10536-42. PubMed ID: 15367620
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
29. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
30. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
Sung JA; Sholtis K; Kirchherr J; Kuruc JD; Gay CL; Nordstrom JL; Bollard CM; Archin NM; Margolis DM
EBioMedicine; 2017 Sep; 23():52-58. PubMed ID: 28803740
[TBL] [Abstract][Full Text] [Related]
31. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.
Wang FX; Xu Y; Sullivan J; Souder E; Argyris EG; Acheampong EA; Fisher J; Sierra M; Thomson MM; Najera R; Frank I; Kulkosky J; Pomerantz RJ; Nunnari G
J Clin Invest; 2005 Jan; 115(1):128-37. PubMed ID: 15630452
[TBL] [Abstract][Full Text] [Related]
32. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.
Persaud D; Palumbo PE; Ziemniak C; Hughes MD; Alvero CG; Luzuriaga K; Yogev R; Capparelli EV; Chadwick EG
AIDS; 2012 Jul; 26(12):1483-90. PubMed ID: 22555165
[TBL] [Abstract][Full Text] [Related]
33. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
34. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte/monocyte apheresis induces sustained increases in CD4 T cells in HIV-1 infected patients with poor CD4 T cell restoration after suppression of viral replication by HAART.
Hasson H; Saniabadi A; Alfano M; Trabattoni D; Ferrante P; Lillo F; Clerici M; Lazzarin A; Beretta A
J Biol Regul Homeost Agents; 2002; 16(1):58-63. PubMed ID: 12003176
[TBL] [Abstract][Full Text] [Related]
36. HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication.
Kulkosky J; Bray S
Curr HIV Res; 2006 Apr; 4(2):199-208. PubMed ID: 16611058
[TBL] [Abstract][Full Text] [Related]
37. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
38. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.
Chun TW; Davey RT; Ostrowski M; Shawn Justement J; Engel D; Mullins JI; Fauci AS
Nat Med; 2000 Jul; 6(7):757-61. PubMed ID: 10888923
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
Shehu-Xhilaga M; Tachedjian G; Crowe SM; Kedzierska K
Curr Med Chem; 2005; 12(15):1705-19. PubMed ID: 16029143
[TBL] [Abstract][Full Text] [Related]
40. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
